Literature DB >> 8376581

Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.

J F Pittet1, M A Matthay, G Pier, M Grady, J P Wiener-Kronish.   

Abstract

The overall objective of these studies was to determine whether IgG antibody to Pseudomonas aeruginosa would modify the acute lung and pleural injury that developed over 24 h after the instillation of 10(10) live P. aeruginosa into the distal airspaces of one lung in unanesthetized sheep. Using a quantitative experimental model to measure protein permeability across the alveolar epithelial, lung endothelial, and pleural mesothelial barriers, the effect of IgG antibody to P. aeruginosa was examined under four different experimental conditions. First, the effect of IgG antibody to P. aeruginosa in the circulation was examined by instilling 10(10) live P. aeruginosa in 5% ovine albumin in sheep that had been vaccinated. Under these conditions, the presence of circulating IgG antibody to P. aeruginosa reduced lung endothelial injury but did not modify the lung epithelial or pleural injury caused by intraalveolar P. aeruginosa. Therefore, the second experimental protocol determined the effect of instilling immune serum from a sheep that had been vaccinated so that IgG antibody to P. aeruginosa was present in both the circulation and in the airspaces along with instillation of live bacteria. Under these conditions, injury to the lung endothelium, alveolar epithelium, and pleural space was completely prevented. Therefore, the third protocol examined the protective effect of instillation of IgG antibody to P. aeruginosa in the airspaces concurrent with the live bacteria. Interestingly, intraalveolar IgG antibody to P. aeruginosa prevented all evidence of lung epithelial and pleural injury, and this effect was associated with a marked decrease in the number of viable bacteria in the lung after 24 h. Therefore, the fourth protocol examined the prophylactic effect of instillation of the specific IgG antibody to P. aeruginosa 24 h before instillation of the bacteria. With this prophylactic regimen, epithelial, endothelial, and pleural injury were prevented, and there was a significant decrease in the number of bacteria recovered from the lung. Thus, delivery of IgG antibody to P. aeruginosa the distal airspaces of the lung alone may provide a novel therapeutic approach to preventing acute pulmonary infection caused by P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376581      PMCID: PMC288261          DOI: 10.1172/JCI116693

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Distribution volumes of [131I]albumin, [14C]sucrose, and 36Cl in sheep lung.

Authors:  S L Selinger; R D Bland; R H Demling; N C Staub
Journal:  J Appl Physiol       Date:  1975-11       Impact factor: 3.531

2.  Cross-protection by Pseudomonas aeruginosa polysaccharides.

Authors:  G B Pier
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

3.  Nosocomial infection surveillance, 1980-1982.

Authors:  J M Hughes; D H Culver; J W White; W R Jarvis; W M Morgan; V P Munn; J L Mosser; T G Emori
Journal:  MMWR CDC Surveill Summ       Date:  1983

4.  Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

5.  Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages.

Authors:  H Y Reynolds; J A Kazmierowski; H H Newball
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

6.  Bacteremic nosocomial pneumonia. Analysis of 172 episodes from a single metropolitan area.

Authors:  C S Bryan; K L Reynolds
Journal:  Am Rev Respir Dis       Date:  1984-05

7.  Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. II. Opsonic, agglutinative, and protective capacities of immunoglobulin G anti-Pseudomonas antibodies.

Authors:  A B Bjornson; J G Michael
Journal:  Infect Immun       Date:  1972-05       Impact factor: 3.441

8.  Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa.

Authors:  G B Pier
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

9.  Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core.

Authors:  M Pollack; A I Huang; R K Prescott; L S Young; K W Hunter; D F Cruess; C M Tsai
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

10.  Solute permeability of the alveolar epithelium in alloxan edema in dogs.

Authors:  R M Nelson; B R McIntyre; E A Egan
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1978-03
View more
  6 in total

Review 1.  The American-European Consensus Conference on ARDS, part 2. Ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling.

Authors:  A Artigas; G R Bernard; J Carlet; D Dreyfuss; L Gattinoni; L Hudson; M Lamy; J J Marini; M A Matthay; M R Pinsky; R Spragg; P M Suter
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

2.  Alveolar response to Pseudomonas aeruginosa: role of the type III secretion system.

Authors:  F Ader; R Le Berre; K Faure; P Gosset; O Epaulard; B Toussaint; B Polack; E Nowak; N B Viget; E Kipnis; B P Guery
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection.

Authors:  K A Brogden; V C Kalfa; M R Ackermann; D E Palmquist; P B McCray; B F Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface.

Authors:  L Imundo; J Barasch; A Prince; Q Al-Awqati
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 5.  Mechanisms of bacterial virulence in pulmonary infections.

Authors:  Samuel M Moskowitz; Jeanine P Wiener-Kronish
Journal:  Curr Opin Crit Care       Date:  2010-02       Impact factor: 3.687

Review 6.  The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response.

Authors:  Teiji Sawa
Journal:  J Intensive Care       Date:  2014-02-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.